References
- National Institute of Clinical Excellence. Guide to the methods of technology appraisal; 2013. https://www.nice.org.uk/article/pmg9/chapter/foreword. Accessed January 2016
- Brazier J, Rowen D, Mavranezouli I, et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Tech Assess 2012;16:1–114
- Longworth L, Yang Y, Young T, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Tech Assess 2014;18:1–224
- Dakin H. Review of studies mapping from quality of life or clinical measures to EQ5D: an online database. Health Qual Life Outcomes 2013;11:151
- Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Qual Life Res 2015:891-911
- Versteegh MM, Leunis A, Luime JJ, et al. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decision Making 2012;32:554–68
- Rowen D, Young T, Brazier J, et al. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Value Health 2012;15:1059–68
- EORTC at a Glance. (2015) The European Organisation for Research and Treatment of Cancer. Available from: http://www.eortc.org/. Accessed January 2016
- van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1723–31
- Petrou S, Rivero-Arias O, Dakin H, et al. Preferred reporting items for studies mapping onto preference-based outcome measures: the maps statement. Int J Technol Assess Health Care 2015;31:230–5
- Austin P, Escobar M, Kopec J. The use of the Tobit model for analyzing measures of health status. Qual Life Res 2000;9:901-10
- Brennan DS, Spencer AJ. Mapping oral health related quality of life to generic health state values. BMC Health Serv Res 2006;6:96
- Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decision Making 2006;26:401–9
- Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70
- Kontodimopoulos N, Aletras VH, Paliouras D, et al. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009;12:1151–7
- Proskorovsky I, Lewis P, Williams CD, et al. Mapping EORTC-QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes 2014;12:35
- Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ HEPAC 2010;11:427–34
- McKenzie L, van der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health 2009;12:167–71
- Jang RW, Isogai PK, Mittman N, Bradbury PA, Shepherd FA, Feld R, Leighl NB. Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer. J Thorac Oncol. 2010;5:1953-7
- Kim EJ, Ko SK, Kang HY. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2012;21:1193-203
- Kim SH, Jo M, Kim H, Ahn J. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health and Quality of Life Outcomes. 2012;10
- Crott R. Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet. Expert Rev Pharmacoecon Outcomes Res 2014;14:569–76